2026 Interim report
Filed with HKEX · Stock code 1177 · · 73 pages · English
8 December 2003 DATE OF LISTING ON GEM BOARD 29 September 2000 DIRECTORS Executive Directors Ms. Tse, Theresa Y Y (Chairwoman) Mr. Tse Ping (Senior Vice Chairman) Ms. Cheng Cheung Ling (Vice Chairwoman) Mr. Tse, Eric S Y (Chief Executive Officer) Mr. Tse Hsin Independent Non-executive Directors Mr. Lu Zhengfei Ms. Lu Hong Mr. Zhang Lu Fu Dr. Li Kwok Tung Donald Dr. Chen Lieping Dr. Lu Bai Executiv
Sino Biopharmaceutical Limited on 6ix
Earlier from Sino Biopharmaceutical
- Voluntary announcement - acceptance of new drug application for TQH2722 injection
- Voluntary announcement - acceptance of new drug application for TQB2102 injection "HER2 bispecific adc"
- Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion
- Once-Yearly Dosing, Targeting Cardiovascular Disorders, First US Patient Enrolled in China-US Phase II Clinical Trial of Hygieia's Kylo-11
- Sino Biopharm Releases 2025 Annual Results: Revenue and Net Profit Maintain Double-Digit Growth, Innovative Product Revenue Exceeds RMB 15 Billion
Later from Sino Biopharmaceutical
- Notification letter and reply form for registered shareholders
- Notification letter and request form for non-registered shareholders
- Voluntary announcement - enter into strategic biosimilars partnership with STADA
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Voluntary announcement - completion of all subjects enrollment in the phase iii registrational clinical trial of TQC3721 inhalation suspension "PDE3/4 inhibitor"
Follow Sino Biopharmaceutical into a list and get an email when it puts out news.
Follow Sino Biopharmaceutical